EluRyng

Last updated on RxList: 10/14/2020
EluRyng Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

What Is EluRyng?

EluRyng (etonogestrel and ethinyl estradiol ring) is an estrogen/progestin combination hormonal contraceptive (CHC) indicated for use by women to prevent pregnancy. EluRyng is available as a generic.

What Are Side Effects of EluRyng?

Side effects of EluRyng include:

Dosage for EluRyng

The dose of EluRyng is one EluRyng inserted in the vagina. The ring must remain in place continuously for three weeks, followed by a one-week ring-free interval.

EluRyng In Children

Safety and efficacy of EluRyng have been established in women of reproductive age. Efficacy is expected to be the same for postpubertal adolescents under the age of 18 and for users 18 years and older. Use of this product before menarche is not indicated.

What Drugs, Substances, or Supplements Interact with EluRyng?

EluRyng may interact with other medicines such as:

Tell your doctor all medications and supplements you use.

EluRyng During Pregnancy and Breastfeeding

EluRyng is not recommended for use during pregnancy because there is no need for pregnancy prevention in a woman who is already pregnant. EluRyng is not recommended while breastfeeding; it can decrease milk production.

Additional Information

Our EluRyng (etonogestrel and ethinyl estradiol ring) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Choosing Your Birth Control Method See Slideshow
EluRyng Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Stop using this medicine and call your doctor at once if you have:

  • signs of a stroke--sudden numbness or weakness (especially on one side of the body), sudden severe headache, slurred speech, problems with vision or balance;
  • signs of a blood clot--sudden vision loss, stabbing chest pain, feeling short of breath, coughing up blood, pain or warmth in one or both legs;
  • heart attack symptoms--chest pain or pressure, pain spreading to your jaw or shoulder, nausea, sweating;
  • toxic shock syndrome--sudden fever, body aches, skin rash, vomiting, diarrhea, and feeling dizzy or light-headed;
  • symptoms of depression--mood changes, thoughts about hurting yourself; or
  • liver problems--loss of appetite, upper stomach pain, tiredness, dark urine, jaundice (yellowing of the skin or eyes).

Common side effects may include:

  • headache, mood changes, decreased sex drive;
  • vaginal irritation or discharge, pain in your cervix;
  • menstrual cramps, breast pain or tenderness;
  • nausea, vomiting, stomach pain;
  • acne or weight gain.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for EluRyng (Etonogestrel and Ethinyl Estradiol Vaginal Ring)

QUESTION

Which of the following are methods for contraception? See Answer
EluRyng Professional Information

SIDE EFFECTS

The following serious adverse reactions with the use of CHCs are discussed elsewhere in the labeling.

  • Serious cardiovascular events and stroke [see BOX WARNING and WARNINGS AND PRECAUTIONS]
  • Vascular events [see WARNINGS AND PRECAUTIONS]
  • Liver disease [see WARNINGS AND PRECAUTIONS]

Adverse reactions commonly reported by CHC users are:

  • Irregular uterine bleeding
  • Nausea
  • Breast tenderness
  • Headache

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Trials with a duration of 6 to 13 28-day cycles provided safety data. In total, 2,501 women, aged 18 to 41 contributed 24,520 cycles of exposure.

Common Adverse Reactions (≥ 2%)

vaginitis (13.8%), headache (including migraine) (11.2%), mood changes (e.g., depression, mood swings, mood altered, depressed mood, affect lability) (6.4%), device-related events (e.g., expulsion/discomfort/foreign body sensation) (6.3%), nausea/vomiting (5.9%), vaginal discharge (5.7%), increased weight (4.9%), vaginal discomfort (4.0%), breast pain/discomfort/tenderness (3.8%), dysmenorrhea (3.5%), abdominal pain (3.2%), acne (2.4%), and decreased libido (2.0%).

Adverse Reactions (≥ 1%) Leading To Study Discontinuation

13.0% of the women discontinued from the clinical trials due to an adverse reaction; the most common adverse reactions leading to discontinuation were device-related events (2.7%), mood changes (1.7%), headache (including migraine) (1.5%) and vaginal symptoms (1.2%).

Serious Adverse Reactions

deep vein thrombosis [see WARNINGS AND PRECAUTIONS], anxiety, cholelithiasis, and vomiting.

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of EluRyng. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune system disorders: hypersensitivity reactions, including anaphylaxis and angioedema

Nervous system disorders: stroke/cerebrovascular accident

Vascular disorders: arterial events (including arterial thromboembolism and myocardial infarction), aggravation of varicose veins

Skin and subcutaneous tissue disorders: urticaria, chloasma

Reproductive system and breast disorders: penile disorders, including local reactions on penis (in male partners of women using EluRyng), galactorrhea

General Disorders and Administration Site Conditions: device breakage (including with concomitant use of intravaginal antimycotic, antibiotic, and lubricant products)

Injury, poisoning and procedural complications: vaginal injury (including associated pain, discomfort, and bleeding) associated with ring breakage

Read the entire FDA prescribing information for EluRyng (Etonogestrel and Ethinyl Estradiol Vaginal Ring)

© EluRyng Patient Information is supplied by Cerner Multum, Inc. and EluRyng Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors